|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500109977 |
|
最近更新日期: Date of Last Refreshed on: |
2025-09-28 14:19:24 |
|
注册时间: Date of Registration: |
2025-09-28 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
基于气体检测的口腔鳞癌智能诊断系统的研发及验证 |
|
Public title: |
Research and development and verification of an intelligent diagnosis system for oral squamous cell carcinoma based on gas detection |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于气体检测的口腔鳞癌智能诊断系统的研发及验证 |
|
Scientific title: |
Research and development and verification of an intelligent diagnosis system for oral squamous cell carcinoma based on gas detection |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘剑楠 |
研究负责人: |
刘剑楠 |
|
Applicant: |
Jiannan Liu |
Study leader: |
Jiannan Liu |
|
申请注册联系人电话: Applicant telephone: |
+86 21 2327 1699 |
研究负责人电话: Study leader's telephone: |
+86 21 2327 1699 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
laurence_ljn@163.com |
研究负责人电子邮件: Study leader's E-mail: |
laurence_ljn@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国上海市黄浦区制造局路639号 |
研究负责人通讯地址: |
中国上海市黄浦区制造局路639号 |
|
Applicant address: |
639 Zhizaoju Road, Huangpu District, Shanghai, China |
Study leader's address: |
639 Zhizaoju Road, Huangpu District, Shanghai, China |
|
申请注册联系人邮政编码: Applicant postcode: |
200001 |
研究负责人邮政编码: Study leader's postcode: |
200001 |
|
申请人所在单位: |
上海交通大学医学院附属第九人民医院 |
||
|
Applicant's institution: |
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine |
||
|
研究负责人所在单位: |
上海交通大学医学院附属第九人民医院 |
||
|
Affiliation of the Leader: |
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
SH9H-2025-T92-2 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海交通大学附属医学院第九人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethic Committee of Shanghai Ninth People's Hospital, 639 Zhizaoju Road, Huangpu District, Shanghai, China |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-04-28 00:00:00 |
||
|
伦理委员会联系人: |
甄红 |
||
|
Contact Name of the ethic committee: |
Hong Zhen |
||
|
伦理委员会联系地址: |
上海市黄浦区制造局路639号上海交通大学医学院附属第九人民医院伦理委员会 |
||
|
Contact Address of the ethic committee: |
Ethic Committee of Shanghai Ninth People's Hospital, 639 Zhizaoju Road, Huangpu District, Shanghai, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 2327 1699 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
上海交通大学医学院附属第九人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国上海市黄浦区制造局路639号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
639 Zhizaoju Road, Huangpu District, Shanghai, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
self-project |
||||||||||||||||||||||
|
Target disease: |
Oral squamous cell carcinoma |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
基于多组学和机器学习,研发一款精准、高效的口腔鳞癌智能诊断模型 |
||||||||||||||||||||||
|
Objectives of Study: |
Based on multi-omics and machine learning, develop an accurate and efficient intelligent diagnostic model for oral squamous cell carcinoma. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
试验组: (1)大于或大于等于18岁以上; (2)男女不限; (3)治疗阶段:未接受、正在接受放化疗治的口腔鳞状细胞癌患者。 (4)诊断组:病理明确诊断为口腔鳞状细胞癌的患者; (5)筛查组:口腔鳞状细胞癌高风险人群: 1)已确诊为口腔白斑、红斑的患者, 2)有家族史或遗传易感性导致的高风险患者, 3)长期暴露于已知致癌因子的患者(如烟草、酒精、槟榔)大于等于10年; 4)口腔中有未明确诊断但高度怀疑癌变的病变。 健康对照组: (1)大于或大于等于18岁以上; (2)男女不限; (3)无口腔鳞癌。 |
||||||||||||||||||||||
|
Inclusion criteria |
Experimental Group: (1) Be 18 years of age or older; (2) No gender restrictions; (3) Treatment Stage: Patients diagnosed with oral squamous cell carcinoma who have not previously received or are currently undergoing radiotherapy and chemotherapy; (4) Diagnostic Group: Patients with a confirmed pathological diagnosis of oral squamous cell carcinoma; (5) Screening Group: High-risk population for oral squamous cell carcinoma, including: ?1) Patients diagnosed with oral leukoplakia or erythroplasia; ?2) Individuals with a family history or genetic predisposition to oral squamous cell carcinoma; ?3) Patients with long-term exposure (10 years or more) to known carcinogens such as tobacco, alcohol, or betel nuts; ?4) Patients with oral lesions highly suspicious of malignancy but not yet diagnosed. Healthy Control Group: (1) Be 18 years of age or older; (2) No gender restrictions; (3) No history or current diagnosis of oral squamous cell carcinoma. |
||||||||||||||||||||||
|
排除标准: |
(1)合并其他部位恶性肿瘤患者; (2)已经参加其他临床研究的患者; (3)存在严重精神疾病或认知障碍,无法理解和遵守研究要求的患者; (4)正在接受可能影响研究结果的药物治疗(如抗生素、消炎药)且无法停药的患者; (5)有吸毒或酗酒行为,影响研究依从性的患者; (6)法律或伦理规定不适合参加本研究的患者; (7)研究者认为不适合纳入研究的患者(如有可能影响研究结果的其他因素)。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Patients with malignant tumors in other parts of the body; (2) Patients who have already participated in other clinical studies; (3) Patients with severe mental illness or cognitive impairment who are unable to understand and comply with the research requirements; (4) Patients who are undergoing drug treatment that may affect the research results (such as antibiotics and anti-inflammatory drugs) and are unable to stop taking the medication; (5) Patients with drug abuse or alcoholism that affects their compliance with the study; (6) Patients who are not suitable to participate in this study as stipulated by law or ethics; (7) Patients who the researcher deems unsuitable for inclusion in the study (such as those with other factors that may affect the study results). |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-07-01 00:00:00至 To 2027-08-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-07-09 00:00:00 至 To 2027-08-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
none |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
原始数据将在试验完成后6个月内公布于中国临床试验注册中心网站(http://www.chictr.org.cn) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Original records will be shared on the Chinese Clinical Trial Registry website (http://www.chictr.org.cn)within 6 months after the trial completed. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
原始数据记录采用上海交通大学医学院附属第九人民医院电子病例采集和管理系统进行保存 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
All of the original data records will be stored in Digital Data Capture and Management Systerm of Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |